A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa) von Lee, J.-M., Annunziata, C.M., Houston, N., Kohn, E.C., Lipkowitz, S., Minasian, L., Nichols, E., Trepel, J., Trewhitt, K., Zia, F., Zimmer, A.D.S.

Volltext

435P Phase II single arm study of durvalumab and olaparib (D+O) in heavily pretreated triple-negative breast cancer (TNBC) with or without germline BRCA mutation (gBRCAm) von Fujii, T., Lipkowitz, S., Zimmer, A.D.S., Villanueva, E., Solarz, B.B., Lee, J-M.

Volltext